Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Validating cancer drug targets through chemical genetics.

Biochimica et biophysica acta - 1 Dec 2010

Burkard Mark E, Jallepalli Prasad V

Abstract excerpt

Targeted therapies for cancer promise to revolutionize treatment by specifically inactivating pathways needed for the growth of tumor cells. The most prominent example of such therapy is imatinib (Gleevec), which targets the BCR-ABL kinase and provides an effective low-toxicity treatment for chronic myelogenous leukemia. This success has spawned myriad efforts to develop similarly targeted drugs for other...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antineoplastic Agents
Share to Drug Discovery
Share to Drug Resistance, Neoplasm

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to BCR gene

Share to Genes, ras

Share to Mutation

Share to Protein Kinase Inhibitors

Share to Signal Transduction

Source

Open in PubMed Open full text

Identifiers

PMID: 20708654
DOI: 10.1016/j.bbcan.2010.08.002
PMCID: PMC3028588

Genes

BCR

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026. Manifest publication-graph-cohort-2026-09-06.1.

Source receipt: pubmed, retrieved 6 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Validating cancer drug targets through chemical genetics.PMID 20708654Read ↗

Chemical genetics: an evolving toolbox for target identification and lead optimization.Semantic proximity Read ↗

Integrating genetic approaches into the discovery of anticancer drugs.Semantic proximity Read ↗

Chemical genetics: elucidating biological systems with small-molecule compounds.Semantic proximity Read ↗

Chemical genetics-based target identification in drug discovery.Semantic proximity Read ↗

From Knowing to Controlling: A Path from Genomics to Drugs Using Small Molecule ProbesSemantic proximity Read ↗

Frontiers in chemical genetics.Semantic proximity Read ↗

Linking tumor mutations to drug responses via a quantitative chemical-genetic interaction map.Semantic proximity Read ↗

Chemical genomic profiling via barcode sequencing to predict compound mode of action.Semantic proximity Read ↗

Genome-wide chemical mutagenesis screens allow unbiased saturation of the cancer genome and identification of drug resistance mutationsSemantic proximity Read ↗

Achieving the promise and avoiding the peril of chemical probes using genetics.Semantic proximity Read ↗

Advances in chemical genetics.Semantic proximity Read ↗

A chemical–genetic interaction map of small molecules using high‐throughput imaging in cancer cellsSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.